PMC:7784786 / 6822-7094 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"236","span":{"begin":21,"end":31},"obj":"Chemical"},{"id":"237","span":{"begin":148,"end":158},"obj":"Chemical"}],"attributes":[{"id":"A236","pred":"tao:has_database_id","subj":"236","obj":"MESH:C000597346"},{"id":"A237","pred":"tao:has_database_id","subj":"237","obj":"MESH:C000597346"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Patient 3 (C) Before itolizumab (D0): alveolar interstitial inflammatory infiltrate in both lung fields, predominantly on the right side. (D) After itolizumab (48 h): radiological improvement with significant decrease of the alveolar interstitial infiltrate of both lungs."}

{"project":"LitCovid-sentences","denotations":[{"id":"T62","span":{"begin":0,"end":272},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Patient 3 (C) Before itolizumab (D0): alveolar interstitial inflammatory infiltrate in both lung fields, predominantly on the right side. (D) After itolizumab (48 h): radiological improvement with significant decrease of the alveolar interstitial infiltrate of both lungs."}